A comparison of the effectiveness of Valtrex vs. Acyclovir

A double-blind, 12-month, placebo- and active-controlled study enrolled immunocompetent adults with a history of 6 or more recurrences per year. Outcomes for the overall study population are shown in Table 1.

Table 1. Recurrence Rates in Immunocompetent Adults at 6 and 12 Months
  6 Months 12 Months
Treatment Arm VALTREX

1 gram q.d.

(n = 269)

ZOVIRAX

400 mg b.i.d.

(n = 267)

Placebo

(n = 134)

VALTREX

1 gram q.d.

(n = 269)

ZOVIRAX

400 mg b.i.d.

(n = 267)

Placebo

(n = 134)

Recurrence free 55% 54% 7% 34% 34% 4%
Recurrences 35% 36% 83% 46% 46% 85%
Unknowns* 10% 10% 10% 19% 19% 10%

*Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.

Subjects with 9 or fewer recurrences per year showed comparable results with VALTREX 500 mg once daily.  

*taken from the official pdr info on valtrex as of 6/1/07

Thanks, Grace.

[HHP home]